, LML4801 Assignment 2(COMPLETE ANSWERS) Semester 1 2026
- DUE 6 April 2026; 100% trusted ,comprehensive and complete
reliable solution with clear explanation.
2 ANSWERS PROVIDED
Patentability and Validity of Biotechnological Inventions under
South African Law
The patentability of biotechnological inventions presents complex legal
challenges, particularly where naturally occurring substances are
isolated and applied in innovative ways. Under the Patents Act 57 of
1978, an invention must meet specific requirements, including novelty,
inventiveness, and industrial applicability, while also not falling within
excluded subject matter such as mere discoveries. In the context of
modern scientific developments, especially in biotechnology, the
distinction between a discovery and a patentable invention is often
difficult to determine. This is because biotechnology often involves
working with substances that already exist in nature, but are manipulated
or applied in new ways. The law must therefore balance encouraging
innovation with preventing monopolies over natural phenomena. These
challenges are particularly relevant in pharmaceutical and biomedical
contexts, where innovation is rapid and highly technical.
This assignment examines the potential patentability and validity of Dr
Dlamini’s invention involving the isolation of a novel photoprotein,
Nalequorin, and its application in a lipid nanoparticle delivery system
for bioimaging. It evaluates whether the invention complies with the
statutory requirements for patent protection in South Africa and
identifies possible risks that may arise during the patent application
process or lead to revocation after grant. The analysis focuses on key
legal requirements such as novelty, inventive step, patentable subject
matter, and sufficiency of disclosure. It also considers practical risks
- DUE 6 April 2026; 100% trusted ,comprehensive and complete
reliable solution with clear explanation.
2 ANSWERS PROVIDED
Patentability and Validity of Biotechnological Inventions under
South African Law
The patentability of biotechnological inventions presents complex legal
challenges, particularly where naturally occurring substances are
isolated and applied in innovative ways. Under the Patents Act 57 of
1978, an invention must meet specific requirements, including novelty,
inventiveness, and industrial applicability, while also not falling within
excluded subject matter such as mere discoveries. In the context of
modern scientific developments, especially in biotechnology, the
distinction between a discovery and a patentable invention is often
difficult to determine. This is because biotechnology often involves
working with substances that already exist in nature, but are manipulated
or applied in new ways. The law must therefore balance encouraging
innovation with preventing monopolies over natural phenomena. These
challenges are particularly relevant in pharmaceutical and biomedical
contexts, where innovation is rapid and highly technical.
This assignment examines the potential patentability and validity of Dr
Dlamini’s invention involving the isolation of a novel photoprotein,
Nalequorin, and its application in a lipid nanoparticle delivery system
for bioimaging. It evaluates whether the invention complies with the
statutory requirements for patent protection in South Africa and
identifies possible risks that may arise during the patent application
process or lead to revocation after grant. The analysis focuses on key
legal requirements such as novelty, inventive step, patentable subject
matter, and sufficiency of disclosure. It also considers practical risks
